



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

23 March 2022  
EMA/67990/2022  
Press office

## Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 21-24 March 2022

During its March 2022 meeting, the CHMP reviewed 2 recommendations for eligibility to PRIME: 2 were denied. The individual outcomes adopted this month are listed below.

---

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union






## Eligibility denied

| Substance type               | Therapeutic area | Therapeutic indication   | Type of data supporting request    | Type of applicant |
|------------------------------|------------------|--|------------------------------------|-------------------|
| Biological Medicinal Product | Oncology         | Treatment of glioblastoma at first recurrence in combination with lomustine. | Nonclinical + Clinical exploratory | SME               |
| Chemical Medicinal Product   | Neurology        | Treatment of Amyotrophic Lateral Sclerosis (ALS)                             | Nonclinical + Clinical exploratory | SME               |

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

## Cumulative overview of PRIME eligibility recommendations adopted by 24 March 2022

■ Granted ■ Denied ■ Out of scope\* ■ Withdrawn



\* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.